Kaitlyn Flegg1, Maxwell J Gelkopf1, Sarah A Johnson1, Helen Dimaras2. 1. Department of Ophthalmology and Vision Sciences (Flegg, Gelkopf, Dimaras), The Hospital for Sick Children, Toronto, Ont.; Department of Neuroscience (Johnson), Evelyn F. and William L. McKnight Brain Institute, University of Florida, Gainesville, Fla.; Department of Ophthalmology and Vision Sciences (Dimaras), Faculty of Medicine, and Division of Clinical Public Health (Dimaras), Dalla Lana School of Public Health, University of Toronto; Child Health Evaluative Sciences Program (Dimaras) and Centre for Global Child Health (Dimaras), SickKids Research Institute, Toronto, Ont. 2. Department of Ophthalmology and Vision Sciences (Flegg, Gelkopf, Dimaras), The Hospital for Sick Children, Toronto, Ont.; Department of Neuroscience (Johnson), Evelyn F. and William L. McKnight Brain Institute, University of Florida, Gainesville, Fla.; Department of Ophthalmology and Vision Sciences (Dimaras), Faculty of Medicine, and Division of Clinical Public Health (Dimaras), Dalla Lana School of Public Health, University of Toronto; Child Health Evaluative Sciences Program (Dimaras) and Centre for Global Child Health (Dimaras), SickKids Research Institute, Toronto, Ont. helen.dimaras@sickkids.ca.
Abstract
BACKGROUND: Retinoblastoma is a childhood cancer of the eye that can have lifelong effects on patients and families. The purpose of this study was for people affected by retinoblastoma, clinicians and researchers to jointly determine the top 10 retinoblastoma research priorities in Canada. METHODS: An adaptation of the James Lind Alliance Priority Setting Partnership (PSP) methodology was employed. People were invited to participate in any stage of the priority-setting process if they were a resident of Canada, and were a patient with retinoblastoma (or a family member or friend of someone diagnosed with retinoblastoma) or a clinician or researcher interested in retinoblastoma. Patients were full partners in study design and implementation, and result dissemination, through involvement in a national working group (1 patient and 9 nonpatients) and steering committee (4 patients and 11 nonpatients). In phase 1 of the study, participants responded to an online survey that asked, "What questions about retinoblastoma would you like to see answered by research?" In phase 2, the steering committee reviewed and refined the list of survey responses and decided on a list of 30 questions to be ranked by means of the nominal group technique in phase 3, a priority-setting workshop. RESULTS: In total, 175 retinoblastoma research questions were suggested by 59 survey participants (38 patients and 21 nonpatients). The categories with the greatest number of questions were genetics and molecular (45 [25.7%]), second cancer (29 [16.6%]) and psychosocial (27 [15.4%]). The top 10 questions as ranked by the workshop participants (10 patients and 10 nonpatients) fell into 7 categories: second cancer (2 questions), follow-up (2), psychosocial (2), treatment (1), diagnosis (1), global health (1) and miscellaneous (1). The early diagnosis of retinoblastoma was identified as the top retinoblastoma research priority in Canada. INTERPRETATION: The list of priorities will serve as a resource for advocacy groups, research teams and funding agencies that focus on retinoblastoma. The inclusion of researchers as participants was an adaptation of the James Lind Alliance PSP methodology and enriched the research prioritization process. Copyright 2020, Joule Inc. or its licensors.
BACKGROUND:Retinoblastoma is a childhood cancer of the eye that can have lifelong effects on patients and families. The purpose of this study was for people affected by retinoblastoma, clinicians and researchers to jointly determine the top 10 retinoblastoma research priorities in Canada. METHODS: An adaptation of the James Lind Alliance Priority Setting Partnership (PSP) methodology was employed. People were invited to participate in any stage of the priority-setting process if they were a resident of Canada, and were a patient with retinoblastoma (or a family member or friend of someone diagnosed with retinoblastoma) or a clinician or researcher interested in retinoblastoma. Patients were full partners in study design and implementation, and result dissemination, through involvement in a national working group (1 patient and 9 nonpatients) and steering committee (4 patients and 11 nonpatients). In phase 1 of the study, participants responded to an online survey that asked, "What questions about retinoblastoma would you like to see answered by research?" In phase 2, the steering committee reviewed and refined the list of survey responses and decided on a list of 30 questions to be ranked by means of the nominal group technique in phase 3, a priority-setting workshop. RESULTS: In total, 175 retinoblastoma research questions were suggested by 59 survey participants (38 patients and 21 nonpatients). The categories with the greatest number of questions were genetics and molecular (45 [25.7%]), second cancer (29 [16.6%]) and psychosocial (27 [15.4%]). The top 10 questions as ranked by the workshop participants (10 patients and 10 nonpatients) fell into 7 categories: second cancer (2 questions), follow-up (2), psychosocial (2), treatment (1), diagnosis (1), global health (1) and miscellaneous (1). The early diagnosis of retinoblastoma was identified as the top retinoblastoma research priority in Canada. INTERPRETATION: The list of priorities will serve as a resource for advocacy groups, research teams and funding agencies that focus on retinoblastoma. The inclusion of researchers as participants was an adaptation of the James Lind Alliance PSP methodology and enriched the research prioritization process. Copyright 2020, Joule Inc. or its licensors.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Helen Dimaras; Kahaki Kimani; Elizabeth A O Dimba; Peggy Gronsdahl; Abby White; Helen S L Chan; Brenda L Gallie Journal: Lancet Date: 2012-03-12 Impact factor: 79.321
Authors: Yacoub A Yousef; Sameh E Soliman; Paulita Pamela P Astudillo; Priya Durairaj; Helen Dimaras; Helen S L Chan; Elise Héon; Brenda L Gallie; Furqan Shaikh Journal: JAMA Ophthalmol Date: 2016-05-01 Impact factor: 7.389
Authors: Jennifer van Dijk; Jaap Huisman; Annette C Moll; Antoinette Y N Schouten-van Meeteren; Pieter D Bezemer; Peter J Ringens; Peggy T Cohen-Kettenis; Saskia M Imhof Journal: Health Qual Life Outcomes Date: 2007-12-03 Impact factor: 3.186
Authors: Jacqueline Ramke; Jennifer R Evans; Esmael Habtamu; Nyawira Mwangi; Juan Carlos Silva; Bonnielin K Swenor; Nathan Congdon; Hannah B Faal; Allen Foster; David S Friedman; Stephen Gichuhi; Jost B Jonas; Peng T Khaw; Fatima Kyari; Gudlavalleti V S Murthy; Ningli Wang; Tien Y Wong; Richard Wormald; Mayinuer Yusufu; Hugh Taylor; Serge Resnikoff; Sheila K West; Matthew J Burton Journal: Lancet Healthy Longev Date: 2022-01
Authors: Peter J Gill; Ann Bayliss; Aubrey Sozer; Francine Buchanan; Karen Breen-Reid; Kim De Castris-Garcia; Mairead Green; Michelle Quinlan; Noel Wong; Shelley Frappier; Katherine Cowan; Carol Chan; Dana Arafeh; Mohammed Rashid Anwar; Colin Macarthur; Patricia C Parkin; Eyal Cohen; Sanjay Mahant Journal: JAMA Netw Open Date: 2022-04-01